Bionyra
Founded 2025 · 7 employees on LinkedIn · 7 known investors
Bionyra Pharma is a clinical-stage biopharmaceutical company developing next-generation mono and multispecific antibodies for severe immune-mediated inflammatory diseases, with an initial focus on atopic dermatitis and inflammatory bowel disease. Its pipeline includes TL1A, TL1A*IL-23p19 bispecific, and IL-25 antibodies with half-life extension technology.
Founders & leadership
Bionyra was founded in 2025 by Frédéric Marrache.
FM
Frédéric MarracheinCo-founder & CEO
Investors · 7
Jeito Capital✓ verifiedParis
Sanofi Ventures✓ verifiedCambridge · $5M
Sofinnova Partners✓ verifiedParis · $540K – $27M
VIVES Partners✓ verifiedWavre · $108K – $7.6M
Apollo Health Ventures✓ verifiedBerlin
Sixty Degree Capital✓ verifiedNorth York
Also in the syndicate · 1
Arkin Bio
Funding
SEC filings, press & company announcements$165M disclosed across 1 round · 2026
- $165MSeries AJun 2026 · 5 sources
Jeito Capital (lead), Sofinnova Partners (lead), Apollo Health Ventures, Arkin Bio, Sanofi Ventures, Sixty Degree Capital, Vives Partners
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Bionyra do?
- Bionyra Pharma is a clinical-stage biopharmaceutical company developing next-generation mono and multispecific antibodies for severe immune-mediated inflammatory diseases, with an initial focus on atopic dermatitis and inflammatory bowel disease. Its pipeline includes TL1A, TL1A*IL-23p19 bispecific, and IL-25 antibodies with half-life extension technology.
- Who founded Bionyra?
- Bionyra was founded by Frédéric Marrache in 2025.
- Who are Bionyra's investors?
- Bionyra's investors include Jeito Capital, Sanofi Ventures, Sofinnova Partners, VIVES Partners, Apollo Health Ventures, Sixty Degree Capital.
- How much funding has Bionyra raised?
- Bionyra has disclosed $165M raised across 1 round.